Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;136(3):371-8.
doi: 10.1007/s00432-009-0664-7. Epub 2009 Aug 27.

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Zołnierek  1 , Pawel Nurzyński, Przemysław Langiewicz, Sylwia Oborska, Anna Waśko-Grabowska, Ewa Kuszatal, Beata Obrocka, Cezary Szczylik
Affiliations

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Zołnierek et al. J Cancer Res Clin Oncol. 2010 Mar.

Abstract

Introduction: This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).

Methods: The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w.

Results: Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047).

Conclusion: Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time to progression of pre-existing bone lesions in mRCC patients receiving sunitinib or sorafenib therapy
Fig. 2
Fig. 2
Time to progression as occurrence of new bone lesions in mRCC patients receiving sunitinib or sorafenib therapy
See this image and copyright information in PMC

References

    1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478 - PubMed
    1. Beeram M, Patnaik A, Rowinsky EK (2005) Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23:6771–6790 - PubMed
    1. Bukowski R, Szczylik C, Stadler W, Simantov R, Shan M (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25(18S):240s (Abstract 5023)
    1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594 - PubMed
    1. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174 - PubMed

Publication types

MeSH terms